Nazlı Ecevit (1900-1985)

Taha Toros Arşivi, Dosya No: 13-Nazlı Ecevi

Valorization of Napier grass via intermediate pyrolysis: Optimization using response surface methodology and pyrolysis products characterization

This study presents first optimization report on pyrolysis oil derived from Napier grass. Effects of temperature, heating rate and nitrogen flow rate on the intermediate pyrolysis of Napier grass biomass in a vertical fixed-bed tubular reactor were investigated collectively. Response surface methodology with central composite design was used for modelling the process and optimization of the process variables. Individual second order polynomial model was found to be adequate in predicting bio-oil, bio-char and non-condensable gas yield. The optimum bio-oil yield of 50.57 wt% was recorded at 600 �C, 50 �C/min and 5 L/min nitrogen flow. The bio-oil obtained throughout this study was two-phase liquid, organic and aqueous phase. The bio-oil, bio-char and non-condensable gas were characterized using standard analytical techniques. The results revealed that the organic phase consists of hydrocarbons and various benzene derivatives, which can be further processed into fuels and valuable chemicals. The aqueous phase was predominantly water, acids, ketones, aldehydes and some phenolics and other water-soluble organics. The non-condensable gas was made up high hydrogen/carbon monoxide ratio suitable for liquid fuel synthesis via Fischer-Tropsch Synthesis. The bio-char was a porous carbonaceous material with high energy content, which can be applied as a solid fuel, adsorbent or source of biofertilizer. This study demonstrated that Napier grass biomass is a viable feedstock for production of high-value bioenergy precursors

p53 as a biomarker and potential target in gastrointestinal stromal tumors

KIT and PDGFRA play a major role in the oncogenic process in gastrointestinal stroma tumors (GIST) and small molecules have been employed with great success to target the KIT and PDGFRA pathways in this cancer. However, approximately 10% of patients with GIST are resistant to current targeted drug therapy. There is a need to explore other potential targets. Although p53 alterations frequently occur in most cancers, studies regarding p53 in GIST have been limited. The CDKN2A/MDM2/p53 axis regulates cell cycle progression and DNA damage responses, which in turn control tumor growth. This axis is the major event required for transformation from low- to high-risk GIST. Generally, p53 mutation is infrequent in GIST, but p53 overexpression has been reported to be associated with high-risk GIST and unfavorable prognosis, implying that p53 should play a critical role in GIST. Also, Wee1 regulates the cell cycle and the antitumor activity of Wee1 inhibition was reported to be p53 mutant dependent. In addition, Wee1 was reported to have potential activity in GIST through the regulation of KIT protein and this mechanism may be dependent on p53 status. In this article, we review previous reports regarding the role of p53 in GIST and propose targeting the p53 pathway as a novel additional treatment strategy for GIST